{"id":542198,"date":"2021-05-07T13:54:01","date_gmt":"2021-05-07T13:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542198"},"modified":"2021-05-07T13:54:01","modified_gmt":"2021-05-07T13:54:01","slug":"autosomal-dominant-polycystic-kidney-disease-adpkd-market-size-share-trends-epidemiology-and-market-research-report-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/autosomal-dominant-polycystic-kidney-disease-adpkd-market-size-share-trends-epidemiology-and-market-research-report-2030-delveinsight_542198.html","title":{"rendered":"Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Size & Share, Trends, Epidemiology and Market Research Report 2030 | DelveInsight"},"content":{"rendered":"
\"Autosomal<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cAutosomal Dominant Polycystic Kidney Disease (ADPKD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease (ADPKD), historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Autosomal Dominant Polycystic Kidney Disease (ADPKD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/p>\n

 <\/p>\n

DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease (ADPKD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease (ADPKD), historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    According to an epidemiological review of ADPKD in the EU, a minimum prevalence of 2.41 and 3.89 per 10,000, and screening prevalence of 3.3 and 4.6 per 10,000 of ADPKD has been found in the studies. Whereas in the registry-derived method, the minimum prevalence was 3.29 per 10,000, and if ADPKD screening was implemented in all European countries, the expected prevalence was 3.96 per 10 000 (Willey, 2017). <\/p>\n<\/li>\n

  2. \n

    Mutations in either the PKD1 or PKD2 gene can cause ADPKD, PKD1, and PKD2 to encode polycystin 1 and polycystin 2 and approximately 1 in 1000 people bear a mutation in either PKD1 or PKD2 genes worldwide. ADPKD affects more than 600,000 Americans and 12.4 million people worldwide. About nine out of every 10 people with PKD have the autosomal dominant form. The prevalence of ADPKD is estimated to range from 1 in 400 to 1000 live births, with 5,000–6,000 new cases diagnosed each year (Rashid, 2018).<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Autosomal Dominant Polycystic Kidney Disease (ADPKD) market report covers a descriptive overview and comprehensive insight of the Autosomal Dominant Polycystic Kidney Disease (ADPKD) epidemiology and Autosomal Dominant Polycystic Kidney Disease (ADPKD) market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. Autosomal Dominant Polycystic Kidney Disease (ADPKD) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Autosomal Dominant Polycystic Kidney Disease (ADPKD) market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

    4. Autosomal Dominant Polycystic Kidney Disease (ADPKD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/autosomal-dominant-polycystic-kidney-disease-market<\/a><\/span><\/strong><\/strong><\/p>\n

    Autosomal Dominant Polycystic Kidney Disease (ADPKD): Overview<\/strong><\/p>\n

    Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. Symptoms vary in severity and age of onset, but usually develop between the ages of 30 and 40. ADPKD is a progressive disease and symptoms tend to get worse over time. The most common symptoms are kidney cysts, pain in the back and the sides and headaches.<\/p>\n

    The key player involved in Autosomal Dominant Polycystic Kidney Disease (ADPKD) market:<\/strong><\/a><\/p>\n

      \n
    1. \n

      Palladio Biosciences, <\/p>\n<\/li>\n

    2. \n

      Sanofi, <\/p>\n<\/li>\n

    3. \n

      Reata Pharmaceuticals, <\/p>\n<\/li>\n

    4. \n

      Regulus Therapeutics<\/p>\n<\/li>\n

    5. \n

      XORTX Therapeutics<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drugs covered<\/strong><\/p>\n

        \n
      1. \n

        Lixivaptan<\/p>\n<\/li>\n

      2. \n

        Venglustat<\/p>\n<\/li>\n

      3. \n

        Bardoxolone<\/p>\n<\/li>\n

      4. \n

        RGLS4326  <\/p>\n<\/li>\n

      5. \n

        XRx-008<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/autosomal-dominant-polycystic-kidney-disease-market<\/a><\/span><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patient Share (%) Overview at a Glance<\/p>\n

        5. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Overview at a Glance<\/p>\n

        6. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Disease Background and Overview<\/p>\n

        7. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Autosomal Dominant Polycystic Kidney Disease (ADPKD)<\/p>\n

        9. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Emerging Therapies<\/p>\n

        12. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Outlook<\/p>\n

        13. Country-Wise Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Autosomal Dominant Polycystic Kidney Disease- Pipeline Insights, 2021 <\/strong><\/p>\n

        “Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market. A detailed picture of the Autosomal Dominant Polycystic Kidney Disease (ADPKD) pipeline landscape is provided, which includes the disease overview and Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment guidelines.<\/p>\n

        Autosomal Dominant Polycystic Kidney Disease – Epidemiology Forecast 2030<\/strong><\/p>\n

        DelveInsight’s ‘Autosomal Dominant Polycystic Kidney Disease (ADPKD) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Autosomal Dominant Polycystic Kidney Disease (ADPKD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cAutosomal Dominant Polycystic Kidney Disease (ADPKD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease (ADPKD), historical and forecasted epidemiology as well as the Autosomal … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542198","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542198"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542198\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}